Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of Lumicitabine in Infants with RSV History
NCT03332459Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of lumicitabine in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of Participants With Asthma After Respiratory Syncytial Virus (RSV) Infection up to 2 years and Percentage of Wheezing Days in Participants Within the First 2 Years After RSV Infection. Started Jan 2018; status: completed.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03332459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332459.